ABT May 2024 124.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:29PM EDT. Market open.
| Previous close | 0.1500 |
| Open | 0.1500 |
| Bid | 0.0000 |
| Ask | 1.1400 |
| Strike | 124.00 |
| Expiry date | 2024-05-10 |
| Day's range | 0.1500 - 0.1500 |
| Contract range | N/A |
| Volume | |
| Open interest | 3 |
PR NewswireAbbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.
ZacksInvestors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Simply Wall St.We Think Some Shareholders May Hesitate To Increase Abbott Laboratories' (NYSE:ABT) CEO Compensation
Key Insights Abbott Laboratories to hold its Annual General Meeting on 26th of April Total pay for CEO Robert Ford...
© 2024 Yahoo. All rights reserved.